Sanofi, Regeneron say rheumatoid arthritis drug Kevzara failed as COVID-19 treatment

Listen
Text
  • Small
  • Medium
  • Large

Sanofi's rheumatoid arthritis drug Kevzara has failed to treat COVID-19 in early clinical trials, the drugmaker said this week.

Sanofi, in partnership with Regeneron, had been testing the drug's effects against COVID-19 because the drug is proven to curb inflammation. But the drug didn't significantly shorten patients' hospital stays in a study involving 420 people, Sanofi said. 

Sanofi said patients were just about as likely to develop severe infections and die while on Kevzara as they were on a placebo. 

Sanofi CEO Paul Hudson has said Kevzara was a "long shot" as a treatment against COVID-19, according to Bloomberg

Regeneron is also testing an antibody drug cocktail it has developed specifically for COVID-19.

 

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars